Novartis agrees to $422.5m in fines
Novartis Pharmaceuticals Corp. will pay $422.5 million in penalties for marketing an epilepsy medicine for unapproved uses and for paying kickbacks to doctors to prescribe it and five other drugs, federal officials said yesterday. Novartis - Epilepsy - Drug - Health - Oxcarbazepine
Read more on Boston Globe
You must log in to post a comment.